Climb Bio, Inc. (CLYM) stock
Close on Nov 12, 2026Market cap $624.33MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $624.33M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.74
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$59.31M
- EPS, diluted
- -$0.82
- Free cash flow
- -$54.54M
- Book value per share
- $2.85
- Diluted shares
- 80M
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $12.25
- Open
- $11.97
- Day's range
- $10.67 – $12.16
- Volume
- 1,346,460
- Average volume (20 days)
- 1,365,029
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.50
- 52-week range
- $1.64 – $18.33
- RSI (14 days)
- 50.7
- Volatility (1 year)
- 97.2%
- Relative volume
- 1.01×
- WACC
- 7.4%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLYM | S&P 500 | Difference | CLYM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.4% | -2.7% | +3.1 pts | ||
| 3 months | -24.5% | -1.7% | −22.7 pts | ||
| Year to date | +171.7% | +11.9% | +159.9 pts | ||
| 1 year | +466.1% | +12.0% | +454.2 pts | ||
| 3 years | +318.1% | +78.2% | +239.9 pts | +61.1% | +21.2% |
| 5 years | -39.4% | +73.2% | −112.6 pts | -9.5% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Climb Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Update
About Climb Bio
Pharmaceutical Preparations
The company is a clinical-stage biotechnology business that develops therapies for individuals suffering from immune-mediated conditions. Its pipeline centers on two investigational monoclonal antibodies obtained through acquisitions and licensing: budoprutug and CLYM116. Budoprutug targets CD19 to deplete B cells in conditions such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. CLYM116 targets APRIL to suppress antibody production in immunoglobulin A nephropathy and related disorders. The company's end users are patients with serious autoimmune and inflammatory diseases.
Company profile, executives and historyClimb Bio stock: common questions
What is Climb Bio's stock price?
CLYM closed at $10.87 on Nov 12, 2026, down 11.27% on the day. Over the past 52 weeks it traded between $1.64 and $18.33.
What is Climb Bio's market cap?
Climb Bio was worth $624.33M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CLYM's P/E ratio?
Climb Bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.82), so it has no meaningful P/E ratio.
Does Climb Bio pay a dividend?
No. Climb Bio has not paid a cash dividend over the last twelve months.
When does Climb Bio report earnings next?
Climb Bio is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CLYM stock performed over the past year?
Including dividends, CLYM returned +466.1% over the past year, against +12.0% for the S&P 500.
How many CLYM shares are sold short?
11M shares were sold short at the latest FINRA report, 35.23% of the float, or 7.8 days of average trading volume.
Who are Climb Bio's competitors?
Companies most similar to Climb Bio by business, industry and size include ZBIO, DNTH, JBIO, ACRS, CRVS.
See a number that looks wrong?